Last reviewed · How we verify
NCT07294599
Morning Versus Evening Patching in Childhood Amblyopia
NA trial testing eye-patching in Amblyopia in 100 participants. Not yet recruiting.
14 June 2026
Quick facts
| Lead sponsor | Yarmouk University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 100 |
| Start date | 14 December 2025 |
| Primary completion | 14 June 2026 |
| Estimated completion | 14 June 2026 |
Drugs / interventions tested
- eye-patching
Conditions studied
- Amblyopia — all drugs for Amblyopia →
Sponsor
Yarmouk University
Who can join
Adults 4 to 8, any sex, with Amblyopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine whether the time of day at which daily occlusion (patching) is administered - morning (08:00-10:00) versus evening (17:00-19:00) - affects the amount of visual-acuity improvement in the amblyopic eye in children with unilateral amblyopia. Rationale: While occlusion therapy remains the mainstay for treatment of childhood amblyopia, existing trials have focused on patching duration, not on the timing of occlusion. Diurnal or chronobiological factors - such as fluctuations in neuroplasticity, attention, compliance, or visual demand during the day - may influence the efficacy of patching. Understanding whether timing matters could help optimize occlusion therapy, improve outcomes, and reduce treatment burden.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07294599
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amblyopia
Currently open trials in the same condition.
- NCT07323953 — Evaluation of AmblyoFix for the Treatment of Unilateral Amblyopia in Children · NA · recruiting
- NCT07281742 — Amblyopia Treatment for Children Aged 8 to 12 Years · NA · recruiting
- NCT07417046 — Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopi · NA · recruiting
- NCT06524882 — Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age · Phase 3 · recruiting
- NCT06380517 — Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age · Phase 3 · recruiting
Other Yarmouk University trials
Trials by the same sponsor.
- NCT06766227 — Smoking Cessation App. in Arabic · NA · not yet recruiting
- NCT04650035 — The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak · completed
- NCT05106803 — Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan · completed
- NCT06289816 — Spleen Preserving Surgery for Splenic Hydatidosis: A Cohort Study on Short and Long-Term Outcomes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07294599 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yarmouk University
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07294599.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing